

IMMUNOLOGY GENETIC TEST REQUISITION FORM

PRECHECK HEALTH SERVICES, INC.

100 Biscayne Blvd., Suite 1611, Miami FL 33132 **Phone:** (305)-203-4711 — CLIA: 10D2210020

appointment@precheckhealth.com — www.precheckhealth.com

PATIENT INFORMATION				
First name		TORMATION	Data	of hirth (MM/DD/MM)
First name	MI Last name		Date	of birth (MM/DD/YYY'r')
Biological sex MRN (medical record number)	Ethnicity Ethnicity			
☐ Male	☐ Asian ☐Black/Afi	rican American 🛮 White/Caucas	sian 🗆 Ashkenazi Jewis	sh□ Hispanic□Other:
Femal	6 11 1 1			
Email address (for billing contact and report access	after clinician releases)	Mo	obile phone	
	<u> </u>		<u> </u>	
Address				
City	State/Prov Zip	/Postal code	Country	
	CLINICAL I	NFORMATION		
Organization name		Phone	e	Fax
Address	City		State/Prov	ZIP/Postal Code Country
	CLINIC	AL TEAM		
Primary clinical contact (contact for general inquir				
Name	NPI	Email address (for report ac	ccess)	
☐ INSURANCE BILLING (attach front	and back of insurance card)			
Attach clinical notes, medical records, and/or lette		revent delays. We do not accer	ot insurance for certain	tests or nationts outside the US
Policyholder name	Patient relationship to	revent delays. We do not deech	or insurance for certain	Medicare insurance
, and the second	□Self □ Spouse □ Child	Other:		billing only (select one):
Primary insurance company name	Primary member ID#	Primary insurance phone Pr	rior-authorization #	☐ Patient was treated as a hospital inpatient in the
Secondary insurance company name	Secondary member ID#	Secondary insurance phoneP	rior-authorization #	last 14 days
				□ Not a hospital patient
PATIENT PAY BILLING	INSTITUTIONAL E	ILLING	PARTNERSHIP	PROGRAMS
PreCheck Health Services, Inc. will send an	Precheck Health Services		PreCheck Health Se	ervices, Inc. partner code:
electronic invoice to the patient email listed above. Insurance will not be billed.		tion address above. Please nould be billed to a different		
	1 1 2 1 2	THE CONTRACT OF		
Label each tube with the patient's full name, date of birth,			specimen.	
	SPECIMEN IN	IFORMATION		
Collection date (MM/DD/YYYY)		Specim	en type	

□ Blood □ Buccal Swab

DNA must be extracted in a CLIA or other suitable certified laboratory. We are unable to accept blood or saliva from patients with allogeneic bone marrow transplants or a blood transfusion <2 weeks prior to specimen collection.





100 Biscayne Blvd., Suite 1611, Miami FL 33132 **Phone:** (305)-203-4711 — CLIA: 10D2210020

appointment@precheckhealth.com — www.precheckhealth.com

QUESTIONNAIRE					
2. Any in 3. Any re in fam 4. Signs	re any previous genetic testing for autoimmune diseases? Yes No herited autoimmune disorders run in families? Yes No current associations of Autoimmune Diseases illy members from the below list? Yes No 3.1. Autoimmune thyroid disease (AITD) 3.2. Systemic sclerosis (SSc) 3.3. Rheumatoid arthritis (RA) 3.4. Systemic lupus erythematosus (SLE). 3.5. Others and symptoms of primary immunodeficiency 4.1. Frequent and recurrent pneumonia 4.2. Bronchitis 4.3. Sinus infections 4.4. Ear infections 4.5. Meningitis or Skin infections 4.6. Inflammation and infection of internal organs 4.7. Blood disorders, such as low platelet count or anemia	5. Is someone else in the family living with neutropenia? Yes No 6. Family or personal history of B-cell lymphoproliferative disorders? Yes No 7. Family or personal history of Human immunodeficiency virus / acquired immune deficiency syndrome (HIV/AIDS)? Yes No 8. Any unusual frequent or severe infections occurs in family members? Yes No 9. Family or personal history of leukemia. immune-complex diseases, like viral hepatitis? No			
PERSON AL Is/was this p ———————————————————————————————————	HISTORY patient affected or symptomatic [†] ?	FAMILY HISTORY Is there a family history of disease for which the patient is being tested? ☐ Yes ☐ No If yes, describe below and attach pedigree and/or clinical notes.			
If yes, de	escribe below and attach clinical notes. Age at diagnosis:	Relationship to patient	Maternal or paternal	Diagnosed condition	Age at diagnosis
[†] Symptomatic r being ordered	means the patient has features or signs known or suspected to be related to the genetic testing land could include findings on physical examination, laboratory tests, or imaging.				
Has this pat	ient had genetic testing before?				
☐ <mark>Yes</mark>	No If yes, write test results and attach the report.				
	COMPREHENSIVE TARGETE	D IMMUNOLO	GY GEN	ETIC TEST	
	Number of Genes: 291				
Gene List	ADA, ADA2, ADAM17, AICDA, AIRE, AK2, AP1S3, AP3B1, AP3D1, ARX, AT C6, C7, C8A, C8B, C9, CARD9, CARD11, CARD14, CASP8, CASP10, CCNC CEBPA, CEBPE, CFD, CFH, CFI, CFP, CFTR, CIITA, CLCN7, COL7A1, COF DCLRE1C, DEF6, DGKE, DNASE1L3, DNASE2, DOCK8, DTNBP1, ELANE, FOXP3, G6PC1, G6PC3, G6PD, GATA2, GFI1, HAX1, HMOX1, HP91, HP93, IGLL1, IKBKB, IKZF1, ILTRAPL1, ILTRN, ILZRA, ILZRG, ILGR, ILGST, ILTR, ITCH, ITGB2, ITK, JAGN1, JAK1, JAK3, KDM5C, KRAS, L1CAM, LCK, LIG1, MED12, MEFV, MID1, MPL, MRTFA, MSH6, MTHFD1, MVK, MYD88, MYH9, NLRC4, NLRP1, NLRP3, NLRP12, NOD2, OAS1, OCRL, ORAI1, PALB2, PAPOLA1, POMP, PRF1, PRG4, PRKCD, PRKDC, PSENEN, PSMB8, PSTPIPRFXANK, RFXAP, RHOH, RIGI, RMRP, RNASEH2A, RNASEH2B, RNASEH2B, SH2D1A, SKIC2, SKIC3, SLC7A7, SLC16A2, SLC29A3, SLC35A1, SLC35C1 STAT2, STAT3, STAT5B, STIM1, STING1, STK4, STX11, STXBP2, TAFAZZ TMC6, TMC8, TNFAIP3, TNFRSF1A, TNFRSF9, TNFRSF13B, TP53, TPP2, VPS13B, VPS45, WAS, WIPF1, WRAP53, XIAP, ZAP70, ZBTB24.	D, CD19, CD27, CD40, C RO1A, CR2, CSF2RA, CS EPG5, ETV6, EXTL3, F9 8, HPS4, HPS5, HPS6, H L10RA, IL10RB, IL12B, II LIG4, LPIN2, LRBA, LY3 NBN, NCF1, NCF2, NCI RN, PAX1, PEPD, PGM3 I, PTEN, PTPRC, RAB2, 2C, RNF168, RORC, RP , SLC37A4, SLC39A4, S IN, TAP1, TAP2, TAPBP,	D40LG, CD46, C SF2RB, CSF3R, N, FANCC, FAS, UWE1, ICOS, IF L12RB1, IL17RA ST, MAGT1, MA F4, NCSTN, NFI N, PI4KA, PIK3C YA, RAC2, RAG1 S6KA3, RTEL1, SLC46A1, SMAR, TBK1, TBX1, T	CD55, CD59, CD79A, CD79B, CD247, C CTLA4, CTPS1, CTSC, CXCR4, CYBA, FASLG, FERMT3, FGD1, FMR1, FOXN FIH1, IFNAR1, IFNAR2, IFNGR1, IFNGR A, IL21R, IL36RN, IRAK4, IRF4, IRF8, IS LT1, MAP3K14, MASP2, MC2R, MCM4, E2L2, NFKB1, NFKB2, NFKBIA, NHEJ1, D, PIK3CG, PIK3R1, PLCG2, PMS2, PN I, RAG2, RASGRP1, RBCK1, REL, RFX RUNX1, SAMD9, SAMHD1, SBDS, SEF CAL1, SOCS1, SP110, SPINK5, SRP72 CF3, TERC, TERT, TICAM1, TINF2, TL	DKL5, CYBB, 1, 2, IGHM, G15, MECP2, NHP2, P, 5, RPING1, , STAT1, R7,
ADDITIO	ONAL ICD CODES	ICD-10 Diagnosis Codes medical necessity of test applicable diagnoses. Ph report the diagnostic co based on individual pati	as required by N ting being ordere hysicians are not des that best des ient diagnoses. It	ence to assist ordering Physicians in provi ledicare and other insurers to determine t ed. This is not an exhaustive list of all required to use these codes but should scribes the reason for performing the test is the Physician's Responsibility to deterr titon of, all health care services ordered.	the

ICD-10 DX Code (s):				
	Group	1		
□ D80.0	Hereditary hypogammaglobulinaemia	□ D84.9	Immunodeÿciency, unspeciÿed	
□ D80.1	Nonfamilial hypogammaglobulinaemia	□ D84.9	Sarcoidosis of lung	
□ D80.2	Selective deÿciency of immunoglobulin A [IgA]	□ D86.1	Sarcoidosis of lymph nodes	
☐ D80.3	Selective deÿciency of immunoglobulin G [IgG] subclasses	□ D86.2	Sarcoidosis of lung with sarcoidosis of lymph nodes	
□ D80.4	Selective deÿciency of immunoglobulin M [lgM]	□ D86.3	Sarcoidosis of skin	
☐ D80.5 ☐ D80.6	Immunodeÿciency with increased immunoglobulin M [IgM] Antibody deÿciency with near-normal immunoglobulins or with	□ D86.8	Sarcoidosis of other and combined sites	
D80.0	hyperimmunoglobulinaemia	□ D86.9	Sarcoidosis, unspeciÿed	
□ D80.7	Transient hypogammaglobulinaemia of infancy	□ D89.0	Polyclonal hypergammaglobulinaemia	
□ D80.8	Other immunodeÿciencies with predominantly antibody defects	□ D89.1	Cryoglobulinaemia	
□ D80.9	Immunodeÿciency with predominantly antibody defects, unspeciÿed	□ D89.2	Hypergammaglobulinaemia, unspeciÿed	
□ D81.0	Severe combined immunodeÿciency [SCID] with reticular dysgenesis	☐ D89.3 ☐ D89.8	Immune reconstitution syndrome Other speciÿed disorders involving the immune mechanism,	
□ D81.1 □ D81.2	Severe combined immunodeÿciency [SCID] with low T- and B-cell numbers	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	not elsewhere classiÿed	
D81.2	Severe combined immunodeÿciency [SCID] with low or normal B-cell numbers	□ D89.9	Disorder involving the immune mechanism, unspeciÿed	
□ D81.3	Adenosine deaminase [ADA] deÿciency	□ M05	Seropositive rheumatoid arthritis	
□ D81.4	Nezelof syndrome	☐ M05.0	Felty syndrome	
□ D81.5	Purine nucleoside phosphorylase [PNP] deÿciency	☐ M05.1	Rheumatoid lung disease	
□ D81.6	Major histocompatibility complex class I deÿciency	□ M05.2	Rheumatoid vasculitis	
☐ D81.7	Major histocompatibility complex class II deÿciency	☐ M05.3	Tillediffaction vascantis	
□ D81.8	Other combined immunodeÿciencies	☐ M05.8	Other seropositive rheumatoid arthritis	
□ D81.9 □ D82.0	Combined immunodeÿciency, unspeciÿed	☐ M05.8	Seropositive rheumatoid arthritis, unspeciÿed	
□ D82.0 □ D82.1	Wiskott-Aldrich syndrome Di George syndrome	☐ M06.0	Seronegative rheumatoid arthritis	
□ D82.1	Immunodeÿciency with short-limbed stature	□ M06.0	Adult-onset Still disease	
□ D82.2	Immunodeÿciency following hereditary defective response to	□ M06.1	Rheumatoid bursitis	
_ 552.5	Epstein-Barr virus	☐ M06.2	Rheumatoid nodule	
□ D82.4	Hyperimmunoglobulin E [IgE] syndrome	□ M06.3	In°amma tory polyarthropathy	
□ D82.8	Immunodeÿciency associated with other speciÿed major defects	□ M06.4	Other speciÿed rheumatoid arthritis	
□ D82.9	Immunodeÿciency associated with major defect, unspeciÿed		Rheumatoid arthritis, unspeciÿed	
□ D83.0	Common variable immunodeÿciency with predominant	☐ M06.9 ☐ M32.0	Drug-induced systemic lupus erythematosus	
	abnormalities of B-cell numbers and function		Systemic lupus erythematosus with organ or system involvement	
□ D83.1	Common variable immunodeÿciency with predominant immunoregulatory T-cell disorders	☐ M32.1 ☐ M32.8		
□ D83.2	Common variable immunodeÿciency with autoantibodies		Other forms of systemic lupus erythematosus	
003.2	to B- or T-cells	☐ M32.9 ☐ M34.0	Systemic lupus erythematosus, unspeciÿed	
□ D83.8	Other common variable immunodeÿciencies	□ M34.0	Progressive systemic sclerosis	
□ D83.9	Common variable immunodeÿciency, unspeciÿed		CR(E)ST syndrome	
□ D84.0	Lymphocyte function antigen-1 [LFA-1] defect	☐ M34.2 ☐ M34.8	Systemic sclerosis induced by drugs and chemicals Other forms of systemic sclerosis	
□ D84.1	Defects in the complement system	☐ M34.8 ☐ M34.9	Systemic sclerosis, unspeciÿed	
□ D84.8	Other speciÿed immunodeÿciencies		Systemic scierosis, unspeciyed	
	Group	2		
□ C16.0	Malignant neoplasm of cardia	☐ C56.2	Malignant neoplasm of left ovary	
☐ C16.1	Malignant neoplasm of fundus of stomach	☐ C56.3	Malignant neoplasm of bilateral ovaries	
☐ C16.2 ☐ C16.3	Malignant neoplasm of body of stomach	☐ C56.9	Malignant neoplasm of unspeciÿed ovary	
☐ C16.3	Malignant neoplasm of pyloric antrum Malignant neoplasm of pylorus	☐ C57.00	Malignant neoplasm of unspeciÿed fallopian tube	
□ C16.5	Malignant neoplasm of lesser curvature of stomach, unspeciÿed	☐ C57.01	Malignant neoplasm of right fallopian tube	
☐ C16.6	Malignant neoplasm of greater curvature of stomach, unspecijed	□ C57.02	Malignant neoplasm of left fallopian tube	
☐ C16.8	Malignant neoplasm of overlapping sites of stomach	☐ C57.10	Malignant neoplasm of unspeciÿed broad ligament	
C16.9	Malignant neoplasm of stomach, unspeciÿed	☐ C57.11 ☐ C57.12	Malignant neoplasm of right broad ligament Malignant neoplasm of left broad ligament	
□ C17.0	Malignant neoplasm of duodenum	☐ C57.12	Malignant neoplasm of unspeciÿed round ligament	
[□ C17.1	Malignant neoplasm of jejunum	☐ C57.21	Malignant neoplasm of right round ligament	
C17.2	Malignant neoplasm of ileum Meckel's diverticulum, malignant	□ C57.22	Malignant neoplasm of left round ligament	
C17.3	Malignant neoplasm of overlapping sites of small intestine	□ C57.3	Malignant neoplasm of parametrium	
☐ C17.8	Malignant neoplasm of small intestine, unspeciÿed	□ C57.4	Malignant neoplasm of uterine adnexa, unspeciÿed	
☐ C18.0	Malignant neoplasm of cecum	☐ C64.1	Malignant neoplasm of right kidney, except renal pelvis	
□ C18.1	Malignant neoplasm of appendix	☐ C64.2	Malignant neoplasm of left kidney, except renal pelvis	
☐ C18.2	Malignant neoplasm of ascending colon	☐ C64.9 ☐ C65.1	Malignant neoplasm of unspeciÿed kidney, except renal pelvis Malignant neoplasm of right renal pelvis	
C18.3	Malignant neoplasm of hepatic °e xure	☐ C65.1	Malignant neoplasm of left renal pelvis	
C18.4	Malignant neoplasm of transverse colon	☐ C65.2	Malignant neoplasm of unspeciÿed renal pelvis	
□ C10.3	Malignant neoplasm of descending colon	☐ C66.1	Malignant neoplasm of right ureter	
□ C18.0	Malignant neoplasm of descending colon Malignant neoplasm of sigmoid colon	☐ C66.2	Malignant neoplasm of left ureter	
C18.7	Malignant neoplasm of overlapping sites of colon	☐ C66.9	Malignant neoplasm of unspeciÿed ureter	
☐ C18.9	Malignant neoplasm of colon, unspeciÿed	□ C68.8	Malignant neoplasm of overlapping sites of urinary organs	
☐ C10.5	Malignant neoplasm of rectosigmoid junction	□ C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	
☐ C20	Malignant neoplasm of rectum	☐ C71.1	Malignant neoplasm of frontal lobe	
☐ C21.2	Malignant neoplasm of cloacogenic zone	☐ C71.2 ☐ C71.3	Malignant neoplasm of temporal lobe Malignant neoplasm of parietal lobe	
☐ C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	☐ C71.3	Malignant neoplasm of occipital lobe	
☐ C22.0	Liver cell carcinoma	☐ C71.4	Malignant neoplasm of cerebral ventricle	
□ C22.1 □ C22.2	Intrahepatic bile duct carcinoma	□ C71.6	Malignant neoplasm of cerebellum	
C22.2	Hepatoblastoma	□ C71.7	Malignant neoplasm of brain stem	

Group 2 (Continued)				
□ C22.3 □ C22.4 □ C22.7 □ C22.8 □ C22.9 □ C24.0 □ C25.0 □ C25.1 □ C25.2 □ C25.3 □ C25.4 □ C25.7 □ C25.8 □ C25.8 □ C25.9 □ C54.1 □ C54.2 □ C54.2 □ C54.3 □ C54.8 □ C54.9 □ C55.8	Angiosarcoma of liver Other sarcomas of liver Other speciÿed carcinomas of liver Malignant neoplasm of liver, primary, unspeciÿed as to type Malignant neoplasm of liver, not speciÿed as primary or secondary Malignant neoplasm of liver, not speciÿed as primary or secondary Malignant neoplasm of biliary tract, unspeciÿed Malignant neoplasm of bady of pancreas Malignant neoplasm of tail of pancreas Malignant neoplasm of tail of pancreas Malignant neoplasm of pancreatic duct Malignant neoplasm of endocrine pancreas Malignant neoplasm of other parts of pancreas Malignant neoplasm of overlapping sites of pancreas Malignant neoplasm of pancreas, unspeciÿed Malignant neoplasm of isthmus uteri Malignant neoplasm of endometrium Malignant neoplasm of myometrium Malignant neoplasm of fundus uteri Malignant neoplasm of overlapping sites of corpus uteri	☐ C71.8 ☐ C71.9 ☐ D12.0 ☐ D12.1 ☐ D12.2 ☐ D12.3 ☐ D12.4 ☐ D12.5 ☐ D12.6 ☐ K63.5 ☐ L85.3 ☐ Z85.00* ☐ Z85.048* ☐ Z85.42* ☐ Z85.42* ☐ Z85.53* ☐ Z85.53* ☐ Z85.59* ☐ Z85.59* ☐ Z85.841*	Malignant neoplasm of overlapping sites of brain Malignant neoplasm of brain, unspeciÿed Benign neoplasm of cecum Benign neoplasm of appendix Benign neoplasm of ascending colon Benign neoplasm of transverse colon Benign neoplasm of fescending colon Benign neoplasm of sigmoid colon Benign neoplasm of colon, unspeciÿed Polyp of colon Xerosis cutis Personal history of malignant neoplasm of unspeciÿed digestive organ Personal history of other malignant neoplasm of large intestine Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus Personal history of malignant neoplasm of other parts of uterus Personal history of malignant neoplasm of ovary Personal history of malignant neoplasm of ovary Personal history of malignant neoplasm of renal pelvis Personal history of malignant neoplasm of other urinary tract organ Personal history of malignant neoplasm of other urinary tract organ Personal history of malignant neoplasm of brain Personal history of colonic polyps Group 4	
	Group 3	□ D01 0	Covers combined improved delicion consiste reticular ducaren esis	
□ D80.5 □ D82.4 □ D80.4 □ D68.0 □ D68.0 □ D68.0 □ D68.0 □ D69.1 □ D69.2	Immunodeÿciency with increased immunoglobulin M [IgM] Hyperimmunoglobulin E [IgE] syndrome Selective deÿciency of immunoglobulin M [IgM] Von Willebrand's disease ngiohemophilia Factor VIII deÿciency with vascular defect Vascular hemophilia Qualitative platelet defects Other nonthrombocytopenic purpura	□ D81.0 □ D81.1 □ D81.2 □ D81.3 □ D81.4 □ D81.5 □ D81.6 □ D81.7	Severe combined immunodeÿciency with reticular dysgenesis Severe combined immunodeÿciency [SCID] with low T- and B-cell numbers Severe combined immunodeÿciency [SCID] with low or normal B-cell numbers Adenosine deaminase [ADA] deÿciency Nezelof syndrome Purine nucleoside phosphorylase [PNP] deÿciency Major histocompatibility complex class I deÿciency Major histocompatibility complex class II deÿciency	
☐ D69.3 ☐ D69.4 ☐ D69.5 ☐ D69.6 ☐ D69.8 ☐ D69.9	Idiopathic thrombocytopenic purpura Other primary thrombocytopenia Secondary thrombocytopenia Thrombocytopenia, unspeciÿed Other speciÿed haemorrhagic conditions Haemorrhagic condition, unspeciÿed	□ D81.8 □ D81.9 □ Q87.0 □ Q87.1 □ Q87.2	Other combined immunodeÿciencies Combined immunodeÿciency, unspeciÿed Congenital malformation syndromes predominantly a" ecting facial appearance Congenital malformation syndromes predominantly associated with short stature Congenital malformation syndromes predominantly involving limbs	
☐ E31 ☐ E31.0 ☐ E31.1 ☐ E31.2 ☐ E31.20	Group 5 Polyglandular dysfunction Autoimmune polyglandular failure Polyglandular hyperfunction Multiple endocrine neoplasia [MEN] syndromes Multiple endocrine neoplasia [MEN] syndrome, unspeciÿed	☐ Q87.2 ☐ Q87.3 ☐ Q87.4 ☐ Q87.5 ☐ Q87.8	Congenital malformation syndromes predominantly involving limbs Congenital malformation syndromes involving early overgrowth Marfan syndrome Other congenital malformation syndromes with other skeletal changes Other speciÿed congenital malformation syndromes, not elsewhere classiÿed	
□ E31.21	Multiple endocrine neoplasia [MEN] type I		Group 7	
□ E31.22 □ E31.23 □ E31.8 □ E31.9 □ D80.0 □ D80.1 □ D80.2 □ D80.3 □ D80.4 □ D80.5 □ D80.6 □ D80.7 □ D80.8 □ D80.9	Multiple endocrine neoplasia [MEN] type IIA Multiple endocrine neoplasia [MEN] type IIB Other polyglandular dysfunction Polyglandular dysfunction, unspeciÿed Hereditary hypogammaglobulinaemia Nonfamilial hypogammaglobulinaemia Selective deÿciency of immunoglobulin A [IgA] Selective deÿciency of immunoglobulin G [IgG] subclasses Selective deÿciency of immunoglobulin M [IgM] Immunodeÿciency with increased immunoglobulin M [IgM] Antibody deÿciency with near-normal immunoglobulins or with hyperimmunoglobulinaemia Transient hypogammaglobulinaemia of infancy Other immunodeÿciencies with predominantly antibody defects Immunodeÿciency with predominantly antibody defects, unspeciÿed Group 6	G11.3 G11.10 G11.11 G11.19 G11.0 G11.2 G11.4 G11.8 G11.9 Q85.00 Q85.01 Q85.01 Q85.01 Q85.02 Q85.09 E21.0	Cerebellar ataxia with defective DNA repair Early-onset cerebellar ataxia, unspeciÿed Friedreich ataxia Other early-onset cerebellar ataxia Congenital nonprogressive ataxia Late-onset cerebellar ataxia Hereditary spastic paraplegia Other hereditary ataxias Hereditary ataxia, unspeciÿed Neuroÿbromatosis, unspeciÿed Neuroÿbromatosis, type 1 Neuroÿbromatosis, type 2 Other neuroÿbromatosis Primary hyperparathyroidism chwannomatosis	
□ D89.8	•	□ Q85.0ຸ □ Q85.03	oÿbromatosis ِ(nonmalignant) chwannomatosis	
□ D89.8	Other speciÿed disorders involving the immune mechanism, not elsewhere classiÿed Disorder involving the immune mechanism, unspeciÿed	☐ Q8 5.1 ☐ Q8 5.8 ☐ Q8 5.9	uberous sclerosis Other phakomatoses, not elsewhere classiÿed Phakomatosis, unspeciÿed	

Patient Informed Consent for Genetic Testing			
I,The Patient authorize PreCheck Health Services, Inc., to conduct genetic testing for IMMUNO GENETIC TEST (Disease and/or Test Name), as ordered by my physician or authorized healthcare provider or my child's or dependent's physician or authorized healthcare provider, and authorize the collection of a sample for the purpose of that testing.			
I acknowledge and consent to the following:			
 My physician or his/her designee (such as a genetic counselor) has fully covered the following: (A) purpose, description and nature of the test and its potential uses; (B) reliability of positive or negative results and the level of certainty that a positive test result for the disease condition serves as a predictor of such disease, the effectiveness and limitations of the genetic test and the meaning of the genetic test results; (C) implications of taking the genetic test, including the medical risks and benefit: 			

- (D) description of the disease or condition tested for;
- (E) the availability and importance of genetic counseling. I acknowledge that I have been provided with information identifying a genetic counselor or medical geneticist from whom I might obtain such counseling and understand that I may seek counseling prior to signing this consent; and
- (F) a positive test result is an indication that I may be predisposed to or have the specific disease or condition tested for and I understand that I may wish to consider further independent testing, consult with my physician or pursue genetic counseling to discuss the test results.
- 2. I authorize and I understand that I will receive the test results from my physician unless I direct otherwise. I understand that I have a right to confidential treatment of my sample and results and that my test results will only be disclosed as authorized in this consent.
- 3. Test results will be retained in accordance with applicable laws. I understand that only my physician's office and/or PreCheck Health Services, Inc. will have access to my sample and that my sample will be used only for the purposes for which I have given my consent.

Patient's Statement

I, the undersigned, have been informed about the test(s) purpose, procedures, possible beneÿts and risks, and I have received a copy of this consent. I have been given the opportunity to ask questions before I sign, and I have been told that I can ask other questions at any time. I voluntarily agree to genetic testing.

PATIENT SIGNATURE*	SIGNATURE OF AUTHORIZED REPRESENTATIVE
PRINT NAME*	PRINT NAME
DATE*	DATE

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in PreCheck Health Services Inc. (PCHS) Informed Consent for Genetic Testing. For orders originating outside the US, the Patient has been informed their personal information and specimen will be transferred to and processed in the US. The Patient has been informed that PCHS may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional). If insurance billing is selected, the Patient has been informed and authorizes PCHS and its designed to release information concerning testing to their insurer. The medical professional agrees to allow PCHS (1) to transfer the information from this TRF to a letter of medical necessity and/or other documentation using the medical professional's name as the signature as well as (2) assist the patient in obtaining pre-test genetic counseling from a third-party service, as required by the patient's insurance provider. I acknowledge that the Patient has agreed that if the Patient's insurer does not reimburse PCHS in full for any reason then PCHS may bill the Patient for the services and the Patient will remit payment to PCHS For amounts the Patient receives from the insurer, the Patient has agreed to remit payment to PCHS for services rendered. I acknowledge that I offered pre-test genetic counseling to the Patient, if required by their insurer. I attest that I am authorized under applicable law to order this test.

ORDERING PHYSICIAN SIGNATURE*	DATE: (MM/DD/YYYY)

Patient Name:,	Patient ID Number:	
Notifier: PreCheck Health Services		

Advance Beneficiary Notice of Non-Coverage (ABN) — All Insurance Providers

Notice to Patients: Your health insurance plan, whether Medicare or a commercial provider, may not cover all tests or services — including those that you and your healthcare provider consider medically necessary. This notice informs you that one or more of the following PreCheck Health tests may not be covered, and you may be financially responsible.

Tests That May Not Be Covered:

Test Category	Examples	Reason for non-coverage	Estimated Cost
PharmacoCheck+	Pharmacogenetic testing	Not deemed medically necessary for your diagnosis	Up to \$295
Germline Custom Panels	ImmunoCheck+, CancerCheck+ NeuroCheck+, MetabolicCheck+ ThyroidCheck+, etc	Insurance exclusions, medical necessity, etc.	Up to \$295

What You Need to Do:

- 1. Review this notice carefully to make an informed decision.
- 2. Ask any questions you may have before proceeding.
- 3. Select one of the options below to indicate your decision.

Note: If you select Option 1 or 2, we may attempt to coordinate with other insurance carriers you have. However, we are not required to do so by Medicare or other insurers.

Patient Options: (Please select only one option)

□ Option 1: I want to receive the PreCheck Health Test(s) listed above. I understand that my insurance provider may not cover these services. I would like a claim submitted to my insurer for an official coverage decision. If denied, I agree to be responsible for payment. I understand that I may appeal the denial in accordance with my insurer's policies.

Option 2: I want to receive the PreCheck Health Test(s) listed above. I do not want a claim submitted to my insurer. I agree to pay out of pocket and understand that I waive my right to an appeal through my insurance plan.

Option 3: I do not want to receive the PreCheck Health Test(s) listed above. I understand that I will not be billed for the service and cannot appeal a non-coverage decision.

Additional Information:

- -If you choose Option 1, PreCheck Health Services will attempt to contact you to discuss your eligibility for financial assistance and may provide you with the option to cancel your order before testing begins. If you have questions about your financial responsibility or coverage, please contact us at (305) 203-4711.
- -This form serves as a courtesy and does not represent an official decision by your insurance provider. If you have questions about your insurance policy or billing, contact your provider directly.
- -For Medicare-specific questions, call 1-800-MEDICARE (1-800-633-4227 / TTY: 1-877-486-2048).

Patient Acknowledgment:

By signing below, you confirm that you have received, reviewed, and understood this	notice. You will also be provided with a copy for your	
records.		
Signature of Patient or Authorized Representative:	. <mark>Date</mark> : / / .	

